Efficacy of Preexposure Prophylaxis with Monoclonal Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic Leukemia
Acta Haematologica · 2024
DOI: 10.1159/000537690 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Haematologica, 2024. Verfasst von Ohad Benjamini und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Division, Chaim Sheba Medical Centre, Tel-Hashomer, Israel. Hauptthemen laut MEDLINE: SARS-CoV-2, Leukemia, Lymphocytic, Chronic, B-Cell, COVID-19, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Preexposure prophylaxis with monoclonal antibodies (mAbs) was developed in addition to COVID-19 vaccine for immunocompromised and those with insufficient immune response, among them patients with CLL. Omicron variant and its sublineages evolved mutations that escape mAbs neutralizing effect, yet the extent of which was not studied.
Methods
We evaluated anti-spike titers and neutralization activity of COVID-19 wild-type (WT), Delta, Omicron, BA.2, BA.4, and BA.5 before and after tixagevimab-cilgavimab (TGM/CGM) dose of 150/150 mg or 300/300 mg in patients with CLL.
Results
70 patients were tested 2 weeks before and 4 weeks after receiving TGM/CGM mAbs. After TGM/CGM, anti-spike ab level increased 170-folds from 13.6 binding antibody unit (BAU)/mL (IQR, 0.4–288) to 2,328 BAU/mL (IQR, 1,681–3,500). Neutralization activity increased in all variants and was 176-folds higher in WT and 55-folds higher in Delta compared to 10-folds higher in Omicron and its sublineages (BA.2 ×11, BA.4 ×4, BA.5 ×18). Over follow-up period of 3 months, 20 patients (29%) with CLL acquired COVID-19 infection, all recovered uneventfully. In a multivariate analysis, anti-spike antibody titer was found a significant predictor for post-TGM/CGM COVID-19 infection.
Conclusion
Efficacy of preexposure prophylaxis with TGM/CGM in patients with CLL is significantly reduced in era of Omicron and its sublineages BA.2, BA.4, and BA.5.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Division, Chaim Sheba Medical Centre, Tel-Hashomer, Israel.
- Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
- Hematology Unit, Bnai Zion Medical Center, Haifa, Israel.
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
- Central Virology Laboratory, Ministry of Health and Sheba Medical Center, Tel-Hashomer, Israel.
- Clinical Microbiology Laboratory, Bnai Zion Medical Center, Haifa, Israel.
Zitieren
APA
Benjamini, O., Tadmor, T., Avigdor, A., Gershon, R., Kliker, L., Fares, F., Atari, N., Laevsky, I., Abdelkader, B., Hod, T., Golan-Shany, O., Mandelboim, M., & Rahav, G. (2024). Efficacy of Preexposure Prophylaxis with Monoclonal Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic Leukemia. Acta Haematologica. https://doi.org/10.1159/000537690
Vancouver
Benjamini O, Tadmor T, Avigdor A, Gershon R, Kliker L, Fares F, et al. Efficacy of Preexposure Prophylaxis with Monoclonal Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic Leukemia. Acta Haematologica. 2024. doi:10.1159/000537690
BibTeX
@article{Benjamini2024,
author = {Benjamini, Ohad and Tadmor, Tamar and Avigdor, Abraham and Gershon, Rotem and Kliker, Limor and Fares, Florin and Atari, Nofar and Laevsky, Ilana and Abdelkader, Bayan and Hod, Tammy and Golan-Shany, Orit and Mandelboim, Michal and Rahav, Galia},
title = {Efficacy of Preexposure Prophylaxis with Monoclonal Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic Leukemia},
journal = {Acta Haematologica},
year = {2024},
doi = {10.1159/000537690}
}
EUVIMED